InvestorsHub Logo
Followers 0
Posts 24
Boards Moderated 0
Alias Born 08/16/2017

Re: None

Tuesday, 08/28/2018 2:16:37 AM

Tuesday, August 28, 2018 2:16:37 AM

Post# of 461
Ulrich/Nohura spin at Targegen, end result BURN on Sanofi......




bout how TargeGen was able to discover its lead drug candidate, TG101348, in-house, and was able to bring it into clinical trials in 18 months with the help of a China-based contract research organization, WuXi Pharmatech. Two years later, the company had proven the concept with data from a mid-stage clinical trial that paved the way for today’s acquisition. Now it will be up to Sanofi to see just how lucrative this drug might be for investors, and valuable it may be for patients. Incyte may reach the market first in this category, Royston says, but he says the TargeGen drug could be the ultimate winner.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CLSD News